Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | NNMT | P40261 | 4/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428407 | 0.84 | NNMT (0.53) | POLBTDP1NNMTRAB9ANPC1 | |
| SCHEMBL8443874 | 0.83 | POLB (0.73) | POLBTDP1NNMTRAB9ANPC1 | |
| SCHEMBL29859234 | 0.83 | TDP1 (1.00) | POLBTDP1NNMTRAB9ANPC1 | |
| SCHEMBL198490 | 0.83 | TDP1 (1.00) | POLBTDP1NNMTRAB9ANPC1 | |
| SCHEMBL31141991 | 0.83 | POLB (0.73) | POLBTDP1NNMTRAB9ANPC1 | |
| SCHEMBL5013567 | 0.81 | NNMT (0.54) | POLBTDP1NNMTHPGDALDH1A1 | |
| SCHEMBL29903108 | 0.81 | NNMT (0.54) | POLBTDP1NNMTHPGDALDH1A1 | |
| SCHEMBL29421563 | 0.81 | NNMT (1.00) | POLBTDP1NNMTRAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL10988320 | 0.81 | TDP1 (0.96) | POLBTDP1NNMTRAB9ANPC1 | |
| SCHEMBL3864064 | 0.81 | POLB (0.71) | POLBTDP1NNMTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| EP-1844020-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | Exelixis, Inc. (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2007024744-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS, INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | claimed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | claimed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | claimed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| EP-3621619-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VISCERAL PAIN | Arena Pharmaceuticals, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| US-6653471-B2 | Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction | NEUROGEN CORPORATION | 2003-11-25 | — | — | US | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | POLB 3619/4885TDP1 2846/4885NNMT 1406/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | POLB 3619/4885TDP1 2846/4885NNMT 1406/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | POLB 3038/4885TDP1 2797/4885NNMT 2977/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | POLB 2796/4885TDP1 2102/4885NNMT 4349/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | POLB 2796/4885TDP1 2102/4885NNMT 4349/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | POLB 2847/4885TDP1 2834/4885NNMT 4522/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | POLB 4185/4885TDP1 4101/4885NNMT 2130/4885 |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | POLB 2796/4885TDP1 2102/4885NNMT 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.